Trailing-twelve-month (TTM) revenue is $454.43 Million with a year-over-year growth of +25.42%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $116,743,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-28 |
| Q4 FY2025Period ended 2025-12-31 | $120,989,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-23 |
| Q1 FY2026Period ended 2026-03-31 | $102,254,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-04 |
| Q2 FY2026Period ended 2026-06-30 | $114,440,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-03 |
| TTM revenue | $454,426,000 |
Current P/S: $2,130,316,607 market capitalization ÷ $454,426,000 TTM revenue = 4.69x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T19:40:12.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $114.44M.
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 20 comparable quarters.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:43:50.673Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20222022-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|
| Diagnostic Test | $227M | $302M | $417M |
| Diagnostic Test, Institutional Customers | $46M | $65M | $70M |
| Diagnostic Test, Self Pay | $8M | $2M | $1M |
| Diagnostic Test, Third Party Insurance | $174M | $235M |
$454.43M
$454.43 Million
+25.42%
vs. $362.32M a year ago (TTM)
+16.28%
5 Year compound annual growth rate
1 Year
+25.42%
3 Year
+24.33%
5 Year
+16.28%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $427.54M | +$122.09M | +39.97% |
| 2024 | $305.45M | +$102.88M | +50.79% |
| 2023 | $202.57M | ($32.13M) | (13.69%) |
| 2022 | $234.69M | +$22.50M | +10.60% |
| 2021 | $212.19M | +$32.87M | +18.33% |
| 2020 |
TTM Growth
+25.42%
3-Year CAGR
+24.33%
5-Year CAGR
+16.28%
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T19:43:50.673Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $345M |
| Product and Service, Other | $7M | $3M | $11M |
|---|
| $179.32M |
| ($16.85M) |
| (8.59%) |
